News | Heart Valve Technology | October 07, 2016

Northwestern Medicine First in Illinois to Implant New FDA-Approved Aortic Valve

Second in the United States to implant Edwards Intuity Elite valve with newly designed deployment system

Northwestern Medicine, Edwards Lifesciences, Intuity Elite suturless aortic valve, first in Illinois

Edwards Intuity valve image courtesy of Northwestern Medicine

October 7, 2016 — A Northwestern Medicine cardiac surgeon was recently the first in Illinois and second in the United States to implant the Edwards Intuity Elite sutureless aortic valve in a patient with coronary artery disease. The device was implanted through the newly U.S. Food and Drug Administration (FDA)-approved, minimally invasive delivery system.

Patrick McCarthy, M.D., executive director of Northwestern Medicine Bluhm Cardiovascular Institute and chief of cardiac surgery at Northwestern Memorial Hospital, led the team that implanted the aortic valve in Robert Kurinsky, a 74-year-old retiree from Oak Brook, Ill. Kurinsky had been treating his slowly deteriorating heart valve since 2012 primarily through medication.

“Using this newly approved valve system helped replace Mr. Kurinsky’s valve in only 12 minutes, which means less trauma to the body and a quicker recovery time,” said McCarthy, who is also the Heller-Sacks Professor of Medicine at Northwestern University Feinberg School of Medicine. “The valve opening is slightly larger than a standard valve, a positive feature for heart function in the coming years. We are always looking to find the safest and most effective means of treating our patients, and I was pleased we could offer this option to Mr. Kurinsky days after the FDA approved it.”

Traditionally, open-heart surgery is the preferred method for valve replacement but increasingly cardiologists and cardiac surgeons are turning to minimally invasive approaches, a critical sea change in the field of cardiac care. McCarthy led the clinical trial at Northwestern Medicine Feinberg School of Medicine for the new valve prior to its approval by the FDA.

The FDA approved, in August 2016, the advanced Edwards Intuity Elite valve system, a deployment device that incorporates some elements of transcatheter aortic valve replacement (TAVR), a minimally invasive valve replacement system.

Kurinsky said he was thrilled to learn of a less invasive option to replace his aortic valve just days before his scheduled surgery. His wife Carol Kurinsky said she could not believe when he picked up the phone in the intensive care unit and said hello the morning after the surgery. She had left him late the night before and he was on a breathing tube.

“I was told my aortic valve was closing, and we came to Northwestern for a second opinion,” said Kurinsky, who works part-time as a golf starter and is an avid international traveler, two avocations he plans to return to soon. “Coming to Northwestern and Dr. McCarthy was the best decision we made.”

For more information:

Related Content

Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Overlay Init